Correspondence | Published:

Supporting the use of artemisinin in combination

Naturevolume 441page282 (2006) | Download Citation

Subjects

Sir

Your News story “Malaria breakthrough raises spectre of drug resistance” (Nature 440, 852–853; 200610.1038/440852b) raises concerns about a new source of artemisinin for treating malaria. The Institute for OneWorld Health (IOWH) strongly supports the World Health Organization guideline that uncomplicated falciparum malaria be treated with artemisinin combination therapies, and not by artemisinin alone as a monotherapy.

We are leading the product development effort for the Artemisinin Project in the developing world and will sell microbially derived artemisinin only for the manufacture of combination antimalarial therapies, except for treatments of severe malaria with parenteral formulations of artemisinin derivatives.

By leveraging the promise of synthetic biology, the IOWH and its partners hope to dramatically reduce the cost of antimalarials for the people who most need them.

Additional information

Contributions to Correspondence may be submitted to corres@nature.com. They should be no longer than 500 words, and ideally shorter. They should be signed by no more than three authors; preferably by one. Published contributions are edited.

Author information

Affiliations

  1. Institute for OneWorld Health, 50 California Street, San Francisco, 94111, California, USA

    • Victoria G. Hale

Authors

  1. Search for Victoria G. Hale in:

About this article

Publication history

Published

Issue Date

DOI

https://doi.org/10.1038/441282d

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing